Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ImmunityBio, Inc.

< Previous 1 2 Next >
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio to Participate in the Jefferies London Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Awarded Seminal Patent on Natural Killer Cells
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio to Present at the Jefferies London Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Company’s Scientific Strategy and Global Expansion
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.